KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Work In Process (2016 - 2018)

Teva Pharmaceutical Industries' Work In Process history spans 10 years, with the latest figure at $590.0 million for Q4 2018.

  • For the quarter ending Q4 2018, Work In Process fell 1.17% year-over-year to $590.0 million, compared with a TTM value of $590.0 million through Dec 2018, down 1.17%, and an annual FY2018 reading of $590.0 million, down 1.17% over the prior year.
  • Work In Process for Q4 2018 was $590.0 million at Teva Pharmaceutical Industries, down from $609.0 million in the prior quarter.
  • The five-year high for Work In Process was $646.0 million in Q1 2018, with the low at $186.0 million in Q4 2014.
  • Average Work In Process over 5 years is $452.2 million, with a median of $593.5 million recorded in 2017.
  • Year-over-year, Work In Process plummeted 73.99% in 2014 and then skyrocketed 200.0% in 2017.
  • Tracing TEVA's Work In Process over 5 years: stood at $186.0 million in 2014, then changed by 0.0% to $186.0 million in 2015, then rose by 6.99% to $199.0 million in 2016, then skyrocketed by 200.0% to $597.0 million in 2017, then fell by 1.17% to $590.0 million in 2018.
  • Per Business Quant, the three most recent readings for TEVA's Work In Process are $590.0 million (Q4 2018), $609.0 million (Q3 2018), and $605.0 million (Q2 2018).